$DMAC
DiaMedica Therapeutics Inc.

2022 Q4 Form 10-Q Financial Statement

#000143774922026609 Filed on November 09, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.703M $1.488M $1.084M
YoY Change 23.85% 37.27% -4.91%
% of Gross Profit
Research & Development $2.270M $1.640M $2.332M
YoY Change 21.33% -29.67% 8.06%
% of Gross Profit
Depreciation & Amortization $6.000K $7.000K $6.000K
YoY Change 0.0% 16.67% -40.0%
% of Gross Profit
Operating Expenses $3.973M $1.640M $2.332M
YoY Change 22.4% -29.67% 8.06%
Operating Profit -$3.128M -$3.416M
YoY Change -8.43% 2.92%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $229.0K $76.00K -$27.00K
YoY Change 3171.43% -381.48% -121.09%
Pretax Income -$3.744M -$3.052M -$3.443M
YoY Change 15.59% -11.36% 7.9%
Income Tax $7.000K $7.000K $7.000K
% Of Pretax Income
Net Earnings -$3.751M -$3.059M -$3.450M
YoY Change 15.56% -11.33% 8.05%
Net Earnings / Revenue
Basic Earnings Per Share -$0.12 -$0.18
Diluted Earnings Per Share -$0.14 -$115.7K -$181.2K
COMMON SHARES
Basic Shares Outstanding 26.44M 26.44M 18.79M
Diluted Shares Outstanding

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $33.50M $36.08M $48.12M
YoY Change -32.74% -25.01% 57.27%
Cash & Equivalents $4.728M $2.771M $16.22M
Short-Term Investments $28.77M $33.31M $31.90M
Other Short-Term Assets $251.0K $331.0K $336.0K
YoY Change 27.41% -1.49% 124.0%
Inventory
Prepaid Expenses $209.0K
Receivables $82.00K $75.00K $104.0K
Other Receivables $2.000K $0.00
Total Short-Term Assets $33.84M $36.49M $48.54M
YoY Change -25.54% -24.82% 56.04%
LONG-TERM ASSETS
Property, Plant & Equipment $136.0K $110.0K $70.00K
YoY Change 94.29% 57.14% 40.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $560.0K $551.0K $127.0K
YoY Change 400.0% 333.86% -22.56%
TOTAL ASSETS
Total Short-Term Assets $33.84M $36.49M $48.54M
Total Long-Term Assets $560.0K $551.0K $127.0K
Total Assets $34.40M $37.04M $48.66M
YoY Change -24.49% -23.88% 55.63%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $734.0K $864.0K $699.0K
YoY Change 44.2% 23.61% -2.92%
Accrued Expenses $1.365M $637.0K $861.0K
YoY Change 41.3% -26.02% 30.85%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $6.000K $7.000K $4.000K
YoY Change 50.0% 75.0% -60.0%
Total Short-Term Liabilities $2.168M $1.542M $1.624M
YoY Change 42.26% -5.05% 12.54%
LONG-TERM LIABILITIES
Long-Term Debt $4.000K $5.000K $4.000K
YoY Change 33.33% 25.0% -60.0%
Other Long-Term Liabilities $396.0K $415.0K $0.00
YoY Change -100.0%
Total Long-Term Liabilities $400.0K $420.0K $4.000K
YoY Change 13233.33% 10400.0% -94.2%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.168M $1.542M $1.624M
Total Long-Term Liabilities $400.0K $420.0K $4.000K
Total Liabilities $2.568M $1.962M $1.628M
YoY Change 68.17% 20.52% 7.67%
SHAREHOLDERS EQUITY
Retained Earnings -$96.20M -$92.40M -$79.30M
YoY Change 16.6% 16.52% 22.55%
Common Stock $0.00 $0.00 $0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $31.80M $35.10M $47.00M
YoY Change
Total Liabilities & Shareholders Equity $34.40M $37.04M $48.66M
YoY Change -24.49% -23.88% 55.63%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q3
OPERATING ACTIVITIES
Net Income -$3.751M -$3.059M -$3.450M
YoY Change 15.56% -11.33% 8.05%
Depreciation, Depletion And Amortization $6.000K $7.000K $6.000K
YoY Change 0.0% 16.67% -40.0%
Cash From Operating Activities -$2.766M -$2.361M -$3.046M
YoY Change -1.36% -22.49% 29.62%
INVESTING ACTIVITIES
Capital Expenditures $32.00K -$43.00K -$2.000K
YoY Change -557.14% 2050.0%
Acquisitions
YoY Change
Other Investing Activities $4.756M $2.115M -$12.83M
YoY Change -154.78% -116.49% -8.39%
Cash From Investing Activities $4.724M $2.072M -$12.83M
YoY Change -154.37% -116.15% -8.37%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $30.00M
YoY Change 30.43%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -1.000K -2.000K 29.87M
YoY Change -94.74% -100.01% 41.01%
NET CHANGE
Cash From Operating Activities -2.766M -2.361M -3.046M
Cash From Investing Activities 4.724M 2.072M -12.83M
Cash From Financing Activities -1.000K -2.000K 29.87M
Net Change In Cash 1.957M -291.0K 13.99M
YoY Change -117.0% -102.08% 189.67%
FREE CASH FLOW
Cash From Operating Activities -$2.766M -$2.361M -$3.046M
Capital Expenditures $32.00K -$43.00K -$2.000K
Free Cash Flow -$2.798M -$2.318M -$3.044M
YoY Change 0.04% -23.85% 29.53%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Net Income Loss
NetIncomeLoss
-9925000 usd
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
5000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-3000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10349000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-3450000 usd
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
35905000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
15000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
244000 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
5000 usd
dei Entity Central Index Key
EntityCentralIndexKey
0001401040
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001401040
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2022Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
-0 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
0 usd
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
0 usd
CY2021 us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
CY2021Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36291
dei Entity Address State Or Province
EntityAddressStateOrProvince
MN
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
55305
dei Entity Registrant Name
EntityRegistrantName
DIAMEDICA THERAPEUTICS INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
A1
dei City Area Code
CityAreaCode
763
dei Entity Address Address Line1
EntityAddressAddressLine1
301 Carlson Parkway, Suite 210
dei Entity Address City Or Town
EntityAddressCityOrTown
Minnetonka
dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-51000 usd
dei Local Phone Number
LocalPhoneNumber
312-6755
dei Security12b Title
Security12bTitle
Voting common shares, no par value per share
dei Trading Symbol
TradingSymbol
DMAC
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 us-gaap Deposits Assets Current
DepositsAssetsCurrent
9000 usd
CY2021Q4 us-gaap Deposits Assets Current
DepositsAssetsCurrent
113000 usd
CY2022Q3 us-gaap Assets Current
AssetsCurrent
36490000 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
45439000 usd
CY2021Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
4000 usd
CY2021Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
3000 usd
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
26443067
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
26443067
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
26443067
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
127667000 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-92426000 usd
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
126576000 usd
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-162000 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-82501000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
35079000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
44024000 usd
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
37041000 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
45551000 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1640000 usd
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2332000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5569000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6894000 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1488000 usd
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1084000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4459000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3506000 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3128000 usd
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3416000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-10028000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-10400000 usd
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
76000 usd
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-27000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
124000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
75000 usd
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3052000 usd
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3443000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-9904000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10325000 usd
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
7000 usd
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
7000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
21000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
21000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-3059000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-3450000 usd
us-gaap Net Income Loss
NetIncomeLoss
-10346000 usd
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-2000 usd
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3054000 usd
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3452000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10036000 usd
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.12
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.18
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.38
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.55
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26443067
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19035713
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26443067
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
18863829
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
44024000 usd
CY2022Q1 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
308000 usd
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-56000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-3508000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
40768000 usd
CY2022Q2 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
365000 usd
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-60000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-3358000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
37715000 usd
CY2022Q3 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
418000 usd
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
5000 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
16219000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-3059000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
35079000 usd
dei Entity Central Index Key
EntityCentralIndexKey
0001401040
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001401040
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36291
dei Entity Registrant Name
EntityRegistrantName
DIAMEDICA THERAPEUTICS INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
A1
dei Entity Address Address Line1
EntityAddressAddressLine1
301 Carlson Parkway, Suite 210
dei Entity Address City Or Town
EntityAddressCityOrTown
Minnetonka
dei Entity Address State Or Province
EntityAddressStateOrProvince
MN
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
55305
dei City Area Code
CityAreaCode
763
dei Local Phone Number
LocalPhoneNumber
312-6755
dei Security12b Title
Security12bTitle
Voting common shares, no par value per share
dei Trading Symbol
TradingSymbol
DMAC
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-2000 usd
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-3622000 usd
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
26014000 usd
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
244000 usd
CY2021Q1 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
511000 usd
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
23145000 usd
CY2021Q2 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
446000 usd
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1000 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
20318000 usd
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
100000 usd
CY2021Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
29867000 usd
CY2021Q3 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
303000 usd
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-2000 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
47036000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
1091000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
1260000 usd
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-118000 usd
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-51000 usd
dmac Noncash Lease Expense
NoncashLeaseExpense
47000 usd
dmac Noncash Lease Expense
NoncashLeaseExpense
43000 usd
us-gaap Depreciation
Depreciation
19000 usd
us-gaap Depreciation
Depreciation
18000 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
238000 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
129000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-55000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-236000 usd
us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
-104000 usd
us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
133000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
355000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-400000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-371000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-48000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8745000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9448000 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
35895000 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
47740000 usd
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
42758000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
49000 usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0 usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
2000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
6814000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-11848000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
29867000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
5000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-5000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
30106000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1936000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
8810000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
4707000 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
7409000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2771000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
446000 usd
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
false
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 usd
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
10000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
0 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-92400000 usd
us-gaap Net Income Loss
NetIncomeLoss
-9900000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8700000 usd
CY2022Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
36100000 usd
CY2022Q3 dmac Working Capital
WorkingCapital
35000000.0 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
35100000 usd
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<i>Concentration of credit risk</i>Financial instruments that potentially expose the Company to concentration of credit risk consist primarily of cash, cash equivalents and marketable securities. The Company maintains its cash balances primarily with two financial institutions. These balances generally exceed federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk in cash and cash equivalents. The Company believes that the credit risk related to marketable securities is limited due to the adherence to an investment policy focused on the preservation of principal.
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
109000 usd
CY2022Q3 us-gaap Interest Payable Current
InterestPayableCurrent
73000 usd
CY2021Q4 us-gaap Interest Payable Current
InterestPayableCurrent
130000 usd
CY2022Q3 us-gaap Deposits Assets Current
DepositsAssetsCurrent
9000 usd
CY2021Q4 us-gaap Deposits Assets Current
DepositsAssetsCurrent
113000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
0 usd
CY2022Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
183000 usd
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
137000 usd
CY2022Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
73000 usd
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
67000 usd
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
110000 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
70000 usd
CY2022Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
303000 usd
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
484000 usd
CY2022Q3 dmac Accrued Clinical Study Costs Current
AccruedClinicalStudyCostsCurrent
230000 usd
CY2021Q4 dmac Accrued Clinical Study Costs Current
AccruedClinicalStudyCostsCurrent
284000 usd
CY2022Q3 dmac Accrued Research And Professional Fees Current
AccruedResearchAndProfessionalFeesCurrent
97000 usd
CY2021Q4 dmac Accrued Research And Professional Fees Current
AccruedResearchAndProfessionalFeesCurrent
191000 usd
CY2022Q3 dmac Accrued Taxes And Other Liabilities Current
AccruedTaxesAndOtherLiabilitiesCurrent
7000 usd
CY2021Q4 dmac Accrued Taxes And Other Liabilities Current
AccruedTaxesAndOtherLiabilitiesCurrent
7000 usd
CY2022Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
637000 usd
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
966000 usd
CY2022Q2 dmac Operating Lease Incremental Borrowing Rate
OperatingLeaseIncrementalBorrowingRate
0.08 pure
us-gaap Operating Lease Cost
OperatingLeaseCost
52000 usd
us-gaap Variable Lease Cost
VariableLeaseCost
25000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
97000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
113000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
116000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
119000 usd
CY2022Q3 dmac Lessee Operating Lease Liability Payments Due Year Six
LesseeOperatingLeaseLiabilityPaymentsDueYearSix
10 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
564000 usd
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
449000 usd
CY2021Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
7653060
CY2021Q3 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
3.92
CY2021Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
30000000.0 usd
CY2021Q3 dmac Proceeds From Issuance Of Common Stock Net
ProceedsFromIssuanceOfCommonStockNet
29900000 usd
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
40000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
244000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
132000 usd
CY2022Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
5724410
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-3059000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-3450000 usd
us-gaap Net Income Loss
NetIncomeLoss
-9925000 usd
us-gaap Net Income Loss
NetIncomeLoss
-10346000 usd
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26443067
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19035713
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26443067
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
18863829
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.12
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.18
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.38
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.55
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
418000 usd
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
303000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1091000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1260000 usd
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1896600
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.22
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
169000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
989398
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.61
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
57813
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
8.78
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
52187
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
4.94
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2775998
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.15
CY2022Q3 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
2775998
us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P7Y7M6D
CY2022Q3 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
4.15
CY2022Q3 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
1464492
us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
P6Y2M12D

Files In Submission

Name View Source Status
dmac-20220930_cal.xml Edgar Link unprocessable
dmtp20220930_10q_htm.xml Edgar Link completed
0001437749-22-026609-index-headers.html Edgar Link pending
0001437749-22-026609-index.html Edgar Link pending
0001437749-22-026609.txt Edgar Link pending
0001437749-22-026609-xbrl.zip Edgar Link pending
dmac-20220930.xsd Edgar Link pending
dmtp20220930_10q.htm Edgar Link pending
ex_440928.htm Edgar Link pending
ex_440933.htm Edgar Link pending
ex_440934.htm Edgar Link pending
ex_440935.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
insert.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
dmac-20220930_def.xml Edgar Link unprocessable
dmac-20220930_lab.xml Edgar Link unprocessable
dmac-20220930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
R46.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending